CRC

MidOcean Partners Makes a Significant Investment in The Re-Sourcing Group, a Leading Professional Services Firm Specializing in Finance & Accounting, Compliance, and IT

Retrieved on: 
Wednesday, January 17, 2024
Finance, Consulting, Professional Services, Asset Management, Human Resources, Knowledge, System One, MidOcean Partners, CCO, CFO, Partnership, CIO, Partner, Investment, Fortune 500, JW, CRC, Engineering, Growth

Re-Sourcing is a leading professional services firm providing staffing, consulting and direct hire solutions that specialize in finance & accounting, legal & compliance and IT.

Key Points: 
  • Re-Sourcing is a leading professional services firm providing staffing, consulting and direct hire solutions that specialize in finance & accounting, legal & compliance and IT.
  • This partnership with MidOcean provides Re-Sourcing with the capital and resources to accelerate its growth and further expand its solutions offerings and geographic footprint.
  • Founded in 2003, Re-Sourcing offers a full suite of services catering to the needs of the office of the CFO, CCO, and CIO.
  • Re-Sourcing’s brands serve a diverse clientele ranging from Fortune 500 customers to growing middle-market companies and leading institutional investors.

Powered by Its Industry-Leading Comprehensive Multi-Modal Database, Caris Life Sciences to Showcase Research at ASCO Gastrointestinal Cancers Symposium 2024

Retrieved on: 
Wednesday, January 17, 2024
Panitumumab, MSI, NGS, Patient, EGFR, Research, Cancer, MD, CTX, ASCO, Diagnosis, Cetuximab, CCA, AI, Society, NCI, Prognosis, TMB, FGFR2, Immunotherapy, FACP, Mutation, MBA, APC, Biomarker, CRC, POA, Abstract, GI, Medicine, Prevalence

IRVING, Texas, Jan. 17, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 11 studies across six solid tumor types at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco. The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.  

Key Points: 
  • "We are proud to again present a wide array of precision oncology research at this year's ASCO GI.
  • Strikingly, patients with early-onset CCA experience better outcomes from immunotherapy even though immune-oncology-relevant markers like MSI and TMB favors average-onset CCA.
  • Two posters use EGFRi-treated CRC samples from the Caris multi-modal database to explore two promising possibilities: APC mutation status and CTX sensitivity score (CTX-S).
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Retrieved on: 
Tuesday, January 16, 2024
Endometrial cancer, Patient, Therapy, Associate, MD, City, MSS, SAN, Liver disease, ASCO, Merck & Co., Poster, Stage 2, Clinical research, Society, Research fellow, Immunotherapy, FACP, Cervical cancer, PRS, PFS, Safety, Liver, Observation, CRC, Pembrolizumab, NCCC, Merck, Physician, Oncology, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Key Points: 
  • “These promising data support further evaluation of this potential best-in-class anti-CTLA-4 antibody, ADG126, in combination with pembrolizumab for MSS CRC patients, including battling new liver lesions in those patients initially without detectable liver metastasis.
  • One of the patients had PD-1 refractory cervical cancer and the other had endometrial cancer.
  • The durable clinical activity of ADG126 in combination with pembrolizumab will continue to be evaluated as a larger cohort of subjects becomes evaluable at the 10 mg/kg Q3W dose level.
  • The clinical profile of ADG126 in combination with pembrolizumab presents a great opportunity for MSS CRC patients that otherwise have limited immunotherapy options available.”

Independent Research Data On Hepatic Artery Infusion (HAI) Therapy Tp Be Featured At ASCO GI Cancer Symposium

Retrieved on: 
Tuesday, January 16, 2024
Neoplasm, Patient, PST, Research, Local, Pancreas, ASCO, Poster, Rectum, Sidney Kimmel, Johns Hopkins, Cholangiocarcinoma, Hepatic artery proper, HAI, Liver disease, Liver, FDA, Progress, CRC, Colorectal cancer, Physician, Pharmaceutical industry

BOSTON, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Intera Oncology, maker of the only FDA-approved implantable pump for Hepatic Artery Infusion (HAI) therapy, announces independent research on HAI therapy will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) January 18-20 in San Francisco, California, USA.

Key Points: 
  • BOSTON, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Intera Oncology, maker of the only FDA-approved implantable pump for Hepatic Artery Infusion (HAI) therapy, announces independent research on HAI therapy will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) January 18-20 in San Francisco, California, USA.
  • Researchers from several top academic medical institutions will present their findings related to HAI therapy through live presentations, oral abstracts, and posters at the symposium.
  • HAI therapy is a powerful treatment for patients with colorectal cancer (CRC) that has spread to the liver and those with intrahepatic cholangiocarcinoma (iCCA).
  • To learn more about evidence supporting the use of HAI therapy, visit Intera Oncology at Exhibitor Booth #4 at #GI24.

EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Saturday, January 13, 2024
DACH, Incidence, Senior counsel, NPV, Cancer, Algorithm, BGM, EMERGE, CRC, Ministry of Social Affairs, AA, Growth, Collection, Labour, Marketing, PMA, PCR, Education, Physician, Death, Colorectal cancer, AI, Commercial, Genetic testing, Gold, Laboratory, PPV, Therapy, Machine learning, Gene expression, Ageing, Mortality, Patient, Hospital, Traction, Health, Partnership, PHI, FG, Big Pharma, Food, FDA, Biomarker, United Nations, Messenger, Clinical trial, Pancreatic cancer, Pharmaceutical industry

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

EQS-News: Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Retrieved on: 
Saturday, January 13, 2024
Patient, Incidence, International business development, Cancer, Colonoscopy, CRC, Colorectal cancer, Gastroenterology

BERKELEY, US – MAINZ, Germany – January 11, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium on January 12th–13th, 2024.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – January 11, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium on January 12th–13th, 2024.
  • The companies joined forces to advance innovative colorectal cancer (CRC) detection in Poland and to increase treatment options as well as survival rates through early detection.
  • The 10th Gdańsk Gastroenterology Symposium gathers national Polish lecturers, scientists, and practitioners who will share the latest insights in gastroenterology, hepatology, and gastrointestinal endoscopy.
  • Mainz Biomed and TestDNA will be present as exhibitor during the two day symposium, also they will open the second day of panel discussions.

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Retrieved on: 
Thursday, January 11, 2024
Patient, Incidence, International business development, Cancer, Colonoscopy, CRC, Colorectal cancer, Gastroenterology

BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium on January 12th–13th, 2024.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium on January 12th–13th, 2024.
  • The companies joined forces to advance innovative colorectal cancer (CRC) detection in Poland and to increase treatment options as well as survival rates through early detection.
  • The 10th Gdańsk Gastroenterology Symposium gathers national Polish lecturers, scientists, and practitioners who will share the latest insights in gastroenterology, hepatology, and gastrointestinal endoscopy.
  • Mainz Biomed and TestDNA will be present as exhibitor during the two day symposium, they will also open the second day of panel discussions.

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 9, 2024
Diabetes, DSM-IV codes, Patient, Leukemia, CTA, PST, Research, CLL, Osteopathic medicine in Canada, Diagnosis, FLT3, NSCLC, Insulin, Cancer, IND, Conference, Safety, DLBCL, FDA, Glycated hemoglobin, PDAC, AML, CRC, Phase, Health Canada, Week, Pharmaceutical industry

Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024.

Key Points: 
  • Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024.
  • A live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events .
  • “2023 was a truly remarkable year for Biomea as we had several positive data readouts in both type 2 diabetes and AML.
  • “We believe BMF-219 has the potential to address the root cause of diabetes and modify its progression in patients.

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Retrieved on: 
Tuesday, January 9, 2024
Bile, Woman, Hyperemesis gravidarum, Research, Biology, Hospital, Weight loss, MSS, FRS, Hepatology, University, ILT3, Liver disease, FGF19, GFRAL, LAIR1, Liver, Doctor of Philosophy, NASH, CRC, Pembrolizumab, Trial of the century, Neoplasm, NGM, SAN, PRS, Public health, Genetic epidemiology, Preterm birth, Vomiting, Cirrhosis, DCR, Dehydration, AASLD, Immunotherapy, Place of birth, Medicine, Pregnancy, Pre-eclampsia, Therapy, ELF, Patient, Bile acid malabsorption, Fibrosis, Nausea, Alkaline phosphatase, PSC, Gastrointestinal disease, CRN, IBS-D, Malnutrition, FDA, Biomarker, Pharmaceutical industry

NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.

Key Points: 
  • NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.
  • Recent landmark genetic research confirmed the link between this rare, devastating condition experienced during pregnancy to higher levels of GDF15.
  • Given our deep expertise in GDF15 biology, we believe we are well positioned to potentially pursue this indication for NGM120.
  • NGM Bio previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC.

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Retrieved on: 
Tuesday, January 9, 2024
Venetoclax, Patient, CRC, MRD, EFS, MD, OS, Acute myeloid leukemia, SLS, COVID, PD, Standard of care, Azacitidine, Food, COVID 19, Disease, Safety, Doctor of Science, Sepsis, Fast Track, FDA, AML, Treatment, CDK9, Pharmaceutical industry

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SLS009 (formerly GFH009), its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.

Key Points: 
  • The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.
  • Importantly, as of the last follow-up, eight of the nine patients enrolled in the 45 mg cohort were alive.
  • The first patient enrolled in the study achieved a complete response (CR) and continues on study in the seventh month with full peripheral blood recovery.
  • Eight patients (89%) remain alive (one patient succumbed to sepsis having previously contracted COVID 19) and six continue treatment.